期刊文献+

模板纯化对HBV拉米呋啶耐药突变检测的检出率影响

Effect of purification methods of serum HBV DNA on sensitivity of detection of HBV lamivuding resistance
原文传递
导出
摘要 目的:研究模板纯化与否对HBV拉米呋啶耐药突变检测的检出率影响。方法:采用离心柱纯化法及直接煮沸裂解法分别处理HBV DNA定量小于104IU/ml的60例患者血清标本,用同一HBV拉米呋啶耐药突变检测荧光PCR试剂盒检测,比较其检出率。结果:HBV DNA定量小于104IU/ml的60例患者血清标本,离心柱纯化组和煮沸裂解组的检出率分别为68.3%和38.3%。结论:低病毒载量的HBV血清样品经离心柱纯化模板后可以明显提高HBV拉米呋啶耐药突变检测的检出率。 Objective:To investigate the effect of purification methods of plasma HBV DNA on sensitivity of detection of HBV lamivuding resistance. Methods :Serum HBV DNA template was prepared by both spin column purification and directly boiling method and HBV Serum samples with 60 clinical samples of 10^4 IU/ml. The effect of purification methods on the assay sensitivity was evaluated by the domestic commercial YMDD mutation kit. Results: The sensitivity of spin column method and boiling method are 68.3% and 38.3% , respectively. Conclusion:The purification of HBV DNA in serum sample by spin column method can remarkably improve the assay sensitivity of HBV lamivuding resistance.
作者 毛雄英 陈辉
出处 《中国卫生检验杂志》 CAS 2009年第2期357-358,共2页 Chinese Journal of Health Laboratory Technology
关键词 乙型肝炎病毒 病毒DNA纯化 突变检测 拉米呋啶耐药突变 Hepatitis B Virus Viral DNA Purification Mutation detection Lamivudine- resistance
  • 相关文献

参考文献12

  • 1Loomba R, Liang TJ. Treatment of chronic hepatitis B [ J ]. Antivir Ther,2007,12 ( Suppl 3 ) : H33 - 41.
  • 2Mauss S, Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy [J]. Expert Rev Anti Infect Ther,2008,6(2) :191 - 195.
  • 3徐蓓,姚光弼,程新建,朱琪泉.拉米夫定治疗慢性乙型肝炎过程中HBV发生YMDD变异的检测[J].肝脏,1999,4(3):141-143. 被引量:18
  • 4刘佳,徐军,王雪飞,王海滨.三种HBV DNA提取方法对荧光定量PCR检测结果影响的比较[J].中华检验医学杂志,2008,31(7):780-783. 被引量:21
  • 5Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patoents receiving oral therapy for chronic hepatitis B [ J ]. Clin Gastroenterol Hepatol, 2007,5 : 890 - 897.
  • 6替比夫定治疗慢性乙型肝炎中国路线图[J].中华传染病杂志,2008,26(5):257-259. 被引量:4
  • 7李正谦,徐克.乙型肝炎病毒基因组自然变异的研究进展[J].
  • 8Lieven S, Carolin VG, Sija DG, et al. Line probe assay for Monitoring drug resistance in hepatitis B virus - infected patients during antiviral therapy [ J ]. J Clin Mircrobio,2000,38 : 702 - 707.
  • 9Wright M, Main J, Thomas HC. Drug -resistant viral hepatitis [ J ]. J Infect,2000,41 : 1 -4.
  • 10Fabien Zoulim. Detection of hepatitis B virus resistance to antivirals [J]. J Clin Virol,2001,21 : 243 -253.

二级参考文献14

  • 1贾继东,侯金林,尹有宽,徐道振,谭德明,牛俊奇,周霞秋,王宇明,朱理珉,贺永文,任红,万谟彬,陈成伟,巫善明,陈亚岗,许家璋,王勤环,魏来,马红.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,15(5):342-345. 被引量:141
  • 2Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007,5:890-897.
  • 3Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007,357: 2576-2588.
  • 4Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients. Hepatology, 2006,44 (4 Suppl 1): 230A.
  • 5Hou J, Yin YK, Xu D,et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B:Results at 1 year of a randomized, double-blind trial. Hepatology, 2008,47:447-454.
  • 6Zeuzem S, Buti M, Gane EJ,et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (The Globe Study). Hepatology, 2007, 46: 681A.
  • 7Reddy KR, Rustgi V, Zeuzem S, et al. Week 24 is the optimal time point for predicting outcomes at 2 years with telbivudine. Global Antiviral J, 2007, 3(Suppl 2):A12.
  • 8Standring DN, Patty A, Chapron C, et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the international GLOBE trial. Gastroenterology, 2007, 132: A766.
  • 9Gane E, Lai CL, Min A, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study. J Hepatol, 2007,46 (Suppl 1): S187.
  • 10Cho YK, Lee JG, Park JM, et al. One-step pathogen specific DNA extraction from whole blood on a centrifugal microfluidic device. Lab Chip, 2007,7:557-564.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部